Qingyuan Tuwei Anchuang Technology Development

Tuwei Anchuang is a clinical-stage biopharmaceutical company based in China, specializing in the development of innovative therapies for metabolic and digestive diseases. The company's primary focus is on addressing high-unmet needs in conditions such as metabolic dysfunction-associated steatohepatitis (MASH/NASH), type 2 diabetes, and obesity. Their lead candidate, TWA-1120, is a thyroid hormone receptor beta (THR-β) selective agonist currently undergoing clinical evaluation. Tuwei Anchuang leverages its expertise in metabolic pathways to advance a pipeline of small molecule candidates designed to improve patient outcomes in chronic metabolic disorders.